THE BRAIN-TARGETED DELIVERY OF DOPAMINE USING A REDOX-BASED CHEMICAL DELIVERY SYSTEM

被引:15
作者
SIMPKINS, JW
BODOR, N
机构
[1] Center for Drug Discovery, University of Florida, Gainesville
基金
美国国家卫生研究院;
关键词
DOPAMINE; BRAIN DELIVERY; REDOX DELIVERY SYSTEM; PARKINSONS DISEASE; HYPERPROLACTINEMIA;
D O I
10.1016/0169-409X(94)90042-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The blood-brain barrier (BBB) blocks the delivery to the brain parenchyma of polar compounds such as the catecholamine, dopamine (DA). Attempts to directly deliver DA to the brain have been unsuccessful, thus impeding the use of neurotransmitter replacement as a strategy for the treatment of neurodegenerative diseases, such as Parkinson's disease (PD) and other conditions in which a dopamine deficiency may be causative, such as chronic hyperprolactinemia. The present review considers the various means of delivering DA to the brain, with a particular focus on the use of a redox-based delivery system for the brain-targeted delivery and localized release of this important neurotransmitter in brain. Results are presented which document successful delivery of DA, its local release and metabolism in the brain and appropriate pharmacological responses to the delivered neurotransmitter. These results open the possibility of treating a variety of brain maladies with novel DA delivery systems.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 25 条
[11]   STUDIES ON THE ENZYMATIC BLOOD-BRAIN-BARRIER - QUANTITATIVE MEASUREMENTS OF DOPA DECARBOXYLASE IN THE WALL OF MICROVESSELS AS RELATED TO THE PARENCHYMA IN VARIOUS CNS REGIONS [J].
HARDEBO, JE ;
FALCK, B ;
OWMAN, C ;
ROSENGREN, E .
ACTA PHYSIOLOGICA SCANDINAVICA, 1979, 105 (04) :453-460
[12]  
HORNYKIE.O, 1973, FED PROC, V32, P183
[13]   ADJUVANT TREATMENT OF PARKINSONS-DISEASE WITH DOPAMINE AGONISTS - OPEN TRIAL WITH BROMOCRIPTINE AND CU-32-085 [J].
JELLINGER, K .
JOURNAL OF NEUROLOGY, 1982, 227 (02) :75-88
[14]   IMMUNOHISTOCHEMICAL LOCALIZATION OF CATECHOL-O-METHYLTRANSFERASE IN CIRCUMVENTRICULAR ORGANS OF THE RAT - POTENTIAL VARIATIONS IN THE BLOOD-BRAIN-BARRIER TO NATIVE CATECHOLS [J].
KAPLAN, GP ;
HARTMAN, BK ;
CREVELING, CR .
BRAIN RESEARCH, 1981, 229 (02) :323-335
[15]   CENTRAL DOPAMINE AGONISTIC ACTIVITY AND MICROSOMAL BIOTRANSFORMATION OF LISURIDE, LERGOTRILE AND BROMOCRIPTINE [J].
KELLER, HH ;
DAPRADA, M .
LIFE SCIENCES, 1979, 24 (13) :1211-1221
[16]  
KOPIN IJ, 1968, J PHARMACOL EXP THER, V161, P271
[17]  
McGeer PL, 1987, MOL NEUROBIOLOGY MAM, P265
[18]   CENTRAL CATECHOLAMINE NEURON SYSTEMS - ANATOMY AND PHYSIOLOGY OF THE DOPAMINE SYSTEMS [J].
MOORE, RY ;
BLOOM, FE .
ANNUAL REVIEW OF NEUROSCIENCE, 1978, 1 :129-169
[19]   DIFFERENTIAL EFFECTS OF DOPAMINE AGONISTS AND HALOPERIDOL ON RELEASE OF PROLACTIN, THYROID STIMULATING HORMONE, GROWTH-HORMONE AND LUTEINIZING-HORMONE IN RATS [J].
MUELLER, GP ;
SIMPKINS, J ;
MEITES, J ;
MOORE, KE .
NEUROENDOCRINOLOGY, 1976, 20 (02) :121-135
[20]  
PARDRIDGE W M, 1975, Critical Reviews in Toxicology, V3, P159, DOI 10.3109/10408447509079857